New Haven

Wallingford-based X9 Inc. raised nearly $13.7 million to develop an AI-guided device that uses ultrasound to help insert dialysis needles, receiving FDA approval for its ultrasound-only version in October.

BioXcel Therapeutics Inc. has named longtime biopharmaceutical executive Mark Pavao as its acting chief commercial officer, choosing an industry veteran to lead its efforts to expand the reach of its drug IGALMI.

Lower interest rates and shifting investor sentiment could make 2026 more active for commercial real estate, though experts warn of multifamily market saturation, slowing industrial development and weakening employment conditions.

The museum plans to acquire a vacant industrial building at 60 Hamilton St., in the city’s Mill River District.

Veradermics Inc., a New Haven-based biopharmaceutical startup developing an oral treatment for pattern hair loss, has filed for an initial public offering.

The number of Connecticut municipalities suing major insulin manufacturers and pharmacy benefit managers over price-fixing continues to grow.

New Haven-based Biohaven Ltd. said Tuesday it expects to raise about $125 million via the sale of common shares to Janus Henderson Investors.

Founder and chief scientist, Yale professor Rob Schoelkopf, will run a research and development center for the combined company in New Haven.

Now the CSCU Center for Quantum and Nanotechnology, or QNT, the facility will serve as a hub for quantum workforce development.

Community Foundation for Greater New Haven is on track to surpass last year's $33.3M fundraising total in CEO Karen DuBois-Walton's first full year. The foundation awarded $31.4M in grants in 2024.